Close mobile menu×

Mark L. Heaney, MD, PhD

Expertise in: 
Cancer Care
Board Certifications: 
Medical Oncology, Hematology
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-5098

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

NY Top Doctor

Board Certifications

  • Medical Oncology
  • Hematology

Clinical Expertise

  • Cancer Care
  • Acute Leukemia
  • Acute Lymphocytic Leukemia
  • Acute Myelogenous Leukemia
  • Acute Myeloid Leukemia
  • Aplastic Anemia
  • Chronic Leukemia
  • Chronic Lymphocytic Leukemia
  • Chronic Lymphoid Leukemia
  • Chronic Myelogenous Leukemia
  • Essential Thrombocythemia
  • Hairy Cell Leukemia
  • Hematologic Malignancy
  • Histiocytosis
  • Immune Thombocytopenic Purpura
  • Large Granular Lymphocytic Leukemia
  • Leukemia
  • Lymphoblastic Leukemia
  • Myelodysplastic Syndrome
  • Myelofibrosis
  • Myeloproliferative Disease
  • Polycythemia Vera
  • Waldenstrom's Macroglobulinemia

Education & Training

  • University of Virginia School of Medicine
  • MD, University of Virginia School of Medicine
  • Residency: Stonybrook University Hospital
  • Fellowship: Memorial Sloan-Kettering Cancer Center

Honors & Awards

  • 2014                              Fellow, American College of Physicians
  • 2008                              Abstract Reviewer and Oral Session Chair, ASH Annual Meeting
  • 2002                              Meet the Professor, ACP-ASIM Annual Meeting
  • 2001                              Hematology Fellows Attending Teaching Award, Memorial Sloan-Kettering
  • 1999                              Who’s Who In America
  • 1998-2001                  Translational Research Award, Leukemia and Lymphoma Society
  • 1996-2001                  Catherine and Frederick R. Adler Chair for Junior Faculty
  • 1993-1996                  NIH Physician Scientist Award
  • 1992                              Sloan-Kettering Clinical Scholar, Charles A. Dana Fellow
  • 1990                              American Cancer Society Clinical Fellow

About Mark Heaney

I have had a long-standing interest in and committment to some of the least common blood cancers. These include the myeloproliferative neoplasms like myelofibrosis, essential thrombocythemia, polycythemia vera and chronic myeloid leukemias but also include even rarer diseases like hairy cell leukemia, mastocytosis, large granular lymphocytic leukemia and the histiocyte diseases-- Langerhan's cell histiocytosis, Rosai-Dorfman disease and Erdheim-Chester disease. In addition to providing care based on personal experience with dozens of patients with these diseases and a comprehensive knowledge of the medical literature and evidence, I have attempted to develop clinical trials for most of these conditions to provide additional therapeutic options and cutting edge treatments.

Mark Heaney received his undergraduate education at Harvard and graduate education at the University of Virginia where he received an M.D. and a Ph.D. in microbiology. After Internal Medicine residency at SUNY Stony Brook, he had fellowship training in Hematology and Medical Oncology at Memorial Sloan-Kettering Cancer Center. Dr. Heaney subsequently joined the faculty at Memorial Sloan-Kettering Cancer Center. As a member of the Leukemia Service for nearly 20 years, Dr. Heaney continued laboratory research, initially studying the cell surface receptors that govern white blood cell development and leukemia cell growth. More recently, he has focused on metabolic differences between leukemia cells and normal cells that can provide insight into how leukemias behave in the individual patient and how they respond to treatment. His finding that vitamin C has the potential to blunt the beneficial effects of chemotherapy has been widely cited.

Dr. Heaney has also been an active clinical investigator. He has been the Principal Investigator of many clinical trials that have aimed at developing new treatments for leukemia. In particular, he has focused on new treatments of the myeloproliferative neoplasms, primary myelofibrosis, polycythemia vera and essential thrombocythemia, but has also studied new treatments for chronic myeloid leukemia, mastocytosis and Langerhans cell histiocytosis in keeping with his clinical expertise in rare blood cancers.

Dr. Heaney joined the faculty at CUMC in January, 2013. He has continued his commitment to caring for patients with blood cancers, developing new treatments including cutting edge clinical trials, and laboratory research that concentrates on translating discoveries from the bench to the bedside. He also renewed his investment in medical education, becoming Director of the Hematology and Medical Oncology Fellowship Program in 2014.

Academic Titles

  • Associate Professor of Medicine at CUMC

Committee/Societies/Council Memberships

American Society of Hematology

American Society of Clinical Oncology

American Society of Physicians

Hairy Cell Leukemia Consortium

Mastocytosis Society

Histiocytosis Society

Erdheim-Chester Disease Global Alliance

Hospital Affiliations

  • NewYork-Presbyterian/Columbia
  • NewYork-Presbyterian/Lawrence Hospital

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Access (Exchange)
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

MagnaCare

Medicare

Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • SelectHealth

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Primary

Research

We have developed a comprehensive clinical trials portfolio to identify new treatment options for patients with all stages of chronic myeloid leukemias, the myeloproliferative neoplasms and myelodysplastic syndrome. For chronic myeloid leukemia, we have clinical trials that also explore the possibility that treatment might be stopped in patients who achieve a high quality response. Our trials include the use of currently-approved drugs administered in novel ways and new agents, either alone or combined with proven therapies, in an effort to improve responses and/or reduce side effects. We are also partnering with research laboratories, both academic and in the pharmaceutical industry to identify new treatments, particularly in the very rare diseases that I treat that do not have proven therapies. Our clinical trials are used as an adjunct to existing treatments in order to provide patients with treatment options that fit best with the patient’s specific needs.

I have also had a long interest in laboratory research focused on the biology of blood cancers. Together with my colleagues we are developing a test that may help identify which patients with chronic blood cancers are more likely to need treatment sooner. We also believe that we can exploit the differences in the biology of the cells in patients with more aggressive disease to identify new targets that will lead to better treatments.

Grants

A RANDOMIZED CONTROLLED PHASE 3 STUDY OF ORAL PACRITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH THROMBOCYTOPENIA (P&S Industry Clinical Trial)

Mar 23 2015 - Mar 23 2020

A PHASE 3, RANDOMIZED STUDY TO EVALUATE THE EFFICACY OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN ANEMIC OR THROMBOCYTOPENIC SUBJECTS WITH PRIMARY MYELOFIBROSIS (P&S Industry Clinical Trial)

Jan 26 2015 - Jan 26 2020

OPEN-LABEL SINGLE ARM PHASE 2 STUDY EVALUATING DASATINIB THERAPY DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CP-CML) WITH STABLE COMPLETE MOLECULAR RESPONSE (CMR) DASFREE (P&S Industry Clinical Trial)

Aug 14 2014 - Aug 14 2019

A PHASE 3, RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY EVALUATING MOMELOTINIB VS. RUXOLITINIB IN SUBJECTS WITH PRIMARY MYELOFIBRSIS (PMF) (P&S Industry Clinical Trial)

Mar 24 2014 - Mar 24 2019

MPD RESEARCH CONSORTIUM (Federal Gov)

Mar 1 2015 - Jun 30 2015

Selected Publications

Selected Bibliography (of more than 50):

  • Heaney ML, Vera JC, Raines MA, Golde DW:  Membrane-associated and soluble granulocyte/macrophage-colony-stimulating factor receptor a subunits are independently regulated in HL-60 cells.  Proc Natl Acad Sci USA 92:2365-2369, 1995
  • Heaney ML, Golde DW:  Myelodysplasia.  New Engl J Med 340:1649-1659, 1999
  • Niu L, Golde DW, Vera JC, Heaney ML:  Kinetic resolution of two mechanisms for high-affinity granulocyte-macrophage colony-stimulating factor binding to its receptor.  Blood  94:3748-3753, 1999
  • Golde DW, Caggiano J, Heaney ML: Cladribine misdosing in hairy cell leukemia: a cause for apparent response failure.  Leukemia Lymphoma 43: 365-367, 2002
  • Brown WE, Coakley FV, Heaney ML: CT of renal involvement by Rosai Dorfman Disease.  Abdominal Imaging 27: 214-216, 2002
  • O’Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK.: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24: 166-173, 2006
  • Paoluzzi L, Gonen M, Gardner JR, Mastrella J, Yang D, Holmlund J, Sorensen M, Leopold L, Manova K, Marcucci G, Heaney ML, O’Connor OA.  Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 111:5350-8, 2008
  • Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, O’Connor OA. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res. 68:8031-8. 2008
  • Koppikar K, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 115:2919-27, 2010
  • Mascarenhas J, Heaney ML, Najfeld V, Hexner E, Abdel-Wahab O, Rampal R, Ravandi F, Petersen B, Roboz G, Feldman E, Podoltsev N, Douer D, Levine R, Tallman M, Hoffman R. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res 36:500-4, 201
  • Heaney ML. Inside Blood: Saving orphans: BRAF targeting of histiocytosis. Blood 121:1487-88, 2013
  • Mallikaratchy P, Gardner J, Nordstrøm LU, Veomett NJ, McDevitt MR, Heaney ML, Scheinberg DA. A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Ther 23: 289-99, 2013
  • Soriano G, Heaney M.  Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications. Curr Opin  Hematol 20:169-75, 2013
  • Sheth A, Escobar-Alvarez S, Gardner J, Ran L, Heaney ML, Scheinberg DA. Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers. Cell Death Dis 5:e1152, 2014
  • Lau N, Heaney ML (Review) Evaluation of Response to First-Line Treatment for Chronic Myeloid Leukemia: Has Imatinib Been Outperformed? Int J Hematologic Oncol 3:153-168, 2014
  • Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel-Wahab O, Heaney ML, Scheel PJ, Feeley NK, Ferrero E, McClain KL, Vaglio A, Colby T, Arnaud L, Haroche J. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124:483-92, 2014
  • Heaney ML. (Review) Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest. Clin Adv Hematol Oncol 12:502-8, 2014
  • Heaney ML. (Editorial) Zeroing in on cereblon. Eur J Haematol 2015 (epub ahead of print)